CX3CR1 and Parkinson disease: MPP+ increases neuronal CX3CL1 levels in rat SN, but administration of CX3CR1 antagonists blocks PD-like pathology, including loss of dopaminergic neurons and motor behavior [108], suggesting that fractalkine can modulate microglial activation in PD models.